Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?

SIMPLE SUMMARY: TP53-mutated acute myeloid leukemia (AML) represents one of the most informative examples of adverse risk AML. As the currently available therapies have not translated to meaningful advances in the survival of these patients, a clinical trial should be the recommendation for all newl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shallis, Rory M., Bewersdorf, Jan P., Stahl, Maximilian F., Halene, Stephanie, Zeidan, Amer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140008/
https://www.ncbi.nlm.nih.gov/pubmed/35626039
http://dx.doi.org/10.3390/cancers14102434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140008/
https://www.ncbi.nlm.nih.gov/pubmed/35626039
http://dx.doi.org/10.3390/cancers14102434

Ejemplares similares